Core Viewpoint - The company reported a revenue of HKD 310 million for the first half of 2025, reflecting a year-on-year growth of 13.4% and a net profit of HKD 75.955 million, which is a 12.7% increase compared to the previous year, indicating strong operational performance and market demand for its products [1] Group 1 - The revenue growth is attributed to the expansion of the company's sales channels and the increasing demand for its product, Bogu Tai [1] - The sustained interest in the company's marketed drugs also contributed to the profit increase [1] - The company's focus on operational efficiency, strict cost control, and precise business execution strategies has proven effective in reinforcing its trajectory of continuous profit growth and long-term value creation [1]
联康生物科技集团(00690)发布中期业绩，净利润7595.5万港元，同比增长12.7%